Santhera Pharmaceuticals Holding AG: Santhera Notes Topline Results from Catalyst Pharmaceuticals' Phase 1 Clinical Study of AGAMREE

Data support AGAMREE's potential use as a treatment across a broad range of chronic inflammatory rare diseases Pratteln, Switzerland, July 1, 2026 - Santhera Pharmaceuticals (SIX: SANN) today notes...